[Mitomycin C and excimer laser]
- PMID: 17344997
- DOI: 10.1590/s0004-27492005000600031
[Mitomycin C and excimer laser]
Abstract
Mitomycin C is an antimetabolite agent that blocks DNA and RNA replication and protein synthesis. It has been used in several ophthalmologic areas, and recently as a modulator of corneal wound healing in excimer laser surgeries. A single application of mitomycin C during surface corneal photoablative surgery seems a safe and efficient therapeutic option for eyes with corneal opacity and/or as prophylaxis in eyes with high risk for corneal opacity development. The use of this drug in photoablative surgery should be cautious until long-term safety results have been reported. The present text presents a review about corneal wound healing with the use of mitomycin C.
Similar articles
-
Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes.Ophthalmology. 2005 Feb;112(2):208-18; discussion 219. doi: 10.1016/j.ophtha.2004.07.035. Ophthalmology. 2005. PMID: 15691552 Clinical Trial.
-
Mitomycin C in highly myopic eyes.Ophthalmology. 2006 Feb;113(2):357; author reply 357-8. doi: 10.1016/j.ophtha.2005.09.031. Ophthalmology. 2006. PMID: 16458104 No abstract available.
-
Long-term effects on corneal keratocytes of mitomycin C during photorefractive keratectomy: a randomized contralateral eye confocal microscopy study.J Refract Surg. 2007 Nov;23(9 Suppl):S1011-4. doi: 10.3928/1081-597X-20071102-06. J Refract Surg. 2007. PMID: 18046999 Clinical Trial.
-
Excimer laser photorefractive keratectomy.Surv Ophthalmol. 1995 Sep-Oct;40(2):89-118. doi: 10.1016/s0039-6257(95)80001-8. Surv Ophthalmol. 1995. PMID: 8533107 Review.
-
Corneal inflammation following corneal photoablative refractive surgery with excimer laser.Surv Ophthalmol. 2013 Jan-Feb;58(1):11-25. doi: 10.1016/j.survophthal.2012.04.005. Surv Ophthalmol. 2013. PMID: 23217585 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources